Andrew Vernon

Centers for Disease Control and Prevention

Also affiliated with Feinstein Institute for Medical Research, The University of Texas at El Paso, National Institute of Allergy and Infectious Diseases, Technical University of Denmark

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence”.

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.44210

N/A

2.0DataRank · unranked

46 citations

Joan M. Mangan, Chee Kin Lam, Michelle Macaraig, Marco M. Salerno, B. Rey deCastro +31 more

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.105938

N/A

2.0DataRank · unranked

57 citations

Payam Nahid, Ekaterina V. Kurbatova, Stefan Goldberg, Lorna Bozeman, William J. Burman +27 more

Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis

Journal of Antimicrobial Chemotherapy(2020)10.1093/jac/dkaa490

N/A

0.854DataRank · unranked

21 citations

Jon Gelfond, Teresa L. Johnson‐Pais, Melissa Engle, John L. Johnson, William C. Whitworth +8 more

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Clinical Infectious Diseases(2022)10.1093/cid/ciac707

N/A

0.726DataRank · unranked

13 citations

Patrick Phillips, Ekaterina V. Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson +17 more

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Clinical Infectious Diseases(2021)10.1093/cid/ciab1037

N/A

0.365DataRank · unranked

5 citations

Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi +20 more

Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine

Contemporary Clinical Trials(2023)10.1016/j.cct.2023.107173

N/A

0.269DataRank · unranked

5 citations

Claire Sadowski, Andrew Vernon, Bert Arevalo, Karlyn D. Beer, Andrey V. Borisov +10 more

Accelerating TB regimen development: introducing FAST-TB

IJTLD OPEN(2024)10.5588/ijtldopen.24.0333

N/A

0.208DataRank · unranked

3 citations

C. Chisholm, F. Jones, Karen Lacourciere, Barbara E. Laughon, Lingadakai Ramachandra +5 more

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis

Trials(2025)10.1186/s13063-025-08973-w

N/A

0.168DataRank · unranked

2 citations

Gustavo E. Velásquez, Russell R. Kempker, Marjorie Z. Imperial, Eric L. Nuermberger, Susan E. Dorman +22 more

Adverse events among persons with TB using in-person vs. electronic directly observed therapy

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.22.0594

N/A

0.104DataRank · unranked

1 citations

Joseph Burzynski, Joan M. Mangan, A. Ross Hill, B. Rey deCastro, Neela D. Goswami +5 more